Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming het aandeel van 2017

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,706   -0,008   (-1,12%) Dagrange 0,704 - 0,716 1.096.456   Gem. (3M) 4,8M

Pharming het aandeel van 2017

Volgen
50.750 Posts
Pagina: «« 1 ... 1048 1049 1050 1051 1052 ... 2538 »» | Laatste | Omlaag ↓
  5. [verwijderd] 27 juli 2017 07:08
    Bericht dat veel te veel is opgemaakt in mijn opinie.

    Na ver zoeken:
    with net sales of $15.3 million in Q2 ($15.5 million in Q1) despite stock level adjustments.

    Vrij zwak, ik verwacht serieuze winstnemingen de komende dagen.
    Had er meer dan verwacht aangezien men duidelijk aangaf dat er een serieuze vraag is in de markt.
  6. [verwijderd] 27 juli 2017 07:09
    Pharming Reports on Financial Results for the First Half of 2017

    Record revenue from product sales up 617% on 2016 marks Pharming’s first half year of operational profitability

    Investment in commercial infrastructure to drive long-term sales growth

    Leiden, The Netherlands, 27 July 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) financial report for the six months ended 30 June 2017.

    The Company will hold a conference call at 13:00 CEDT/ 07:00 EDT today: dial-in details can be found on page 7.

    Operational Highlights

    Accelerated the delivery of operating profitability as a result of strategic decision to reacquire commercial rights to RUCONEST® in North America
    Positive EMA amendment to the marketing authorization in Europe to allow self-administration of RUCONEST® for HAE attacks with a new custom-designed RUCONEST® Administration Kit
    Integration of the Ruconest North America business acquired from Valeant Pharmaceuticals International, inc. in December 2016 into Pharming is on track, with full transition of services from Valeant completed
    Completed investment in expanding US commercialization team
    Successfully refinanced company debt on more favourable commercial terms in order to recover dilutive share capital and release short and medium term cash to invest in accelerating commercialization
    Financial Highlights

    Revenues from product sales for the half year increased by 617% to €30.1 million (HY 2016: €4.2 million), as a result of the combined effect of receiving all of the revenue from US product sales (instead of the previous 30% supply share of net sales) and increasing patient numbers and product sales
    Total revenues increased by 477% to €30.6 million (including €0.5 million of license revenue) from €5.3 million (including €1.1 million in license revenue) in HY 2016
    Operating results improved to a profit of €4.2 million from a loss of €6.2 million in HY 2016, despite a considerable increase in commercialization activities, especially in the US
    The net result was a loss of €30.2 million (HY 2016: loss of €6.7 million), mainly as a result of non-cash financing expenses required to be shown under IFRS associated with the extinction of the Amortising Convertible Bonds 2017/2018 and replacement of the previous debt facility
    The company’s cash position decreased from €32.1 million at year-end 2016 to €25.2 million at 30 June 2017 (up from €21.7 million at 30 June 2016), largely due to late payments by debtors of revenues relating to US sales.
    Sijmen de Vries, CEO, said:

    “We are delighted with a second quarter of profitable operations, even after increased costs as we finish our integration and infrastructure investments. Now that our capital position is properly secured following the refinancing in May/July 2017, we can look forward to more stable growth as the big one-off accounting costs have been taken in this quarter.”

  9. [verwijderd] 27 juli 2017 07:11

    Chief Executive Officer’s Comment

    Our strategic decision to re-acquire the commercial rights to sell RUCONEST® in North America has significantly increased revenue and profit generation for the first half of the year compared to the first half of 2016.

    Product sales for the half year increased by 617% to €30.1 million (HY 2016: €4.2 million). The positive sales momentum in the US continued in Q2, following higher than expected sales in Q1, with net sales of $15.3 million in Q2 ($15.5 million in Q1) despite stock level adjustments.

    Combined with ongoing growth in the number of US patients entering our full patient care plan, RUCONEST® SOLUTIONS, and new European patients starting RUCONEST® therapy with our recently introduced EU home use kit, we expect sales to increase in H2.

    Our strategy of increasing market access in the US with our sales, market access, nursing and patient management teams, and in the EU with continued expansion of our direct commercialization efforts, is driving the growth in new patients using RUCONEST®. As previously announced, marketing costs have increased as a direct result of hiring additional US personnel and start-up investments in marketing activities.

    Underlying sales volumes somewhat increased in Q2. On a reported basis, however, Q2 sales were slightly reduced to €14.9 million, from €15.2 million in Q1, reflecting the adverse movement in exchange rates (the dollar weakened against the euro). This was offset by a better performance in the EU and the Rest of the World (RoW) sales, which were up from €0.7 million in Q1 to €0.9 million in Q2.

    Gross profits reduced in line with the reduction in sales expressed in euros from €13.8 million in Q1 to €13.2 million in Q2, also reflecting slightly higher costs of goods and the higher mix of lower-margin RoW sales. We remain focused on increasing efficiency and controlling costs.

    Operating profit for the first half of the year was €4.2 million, of which €3.9 million was recorded in Q1. As previously guided, we have invested in expanding the US sales and marketing team and making further significant investments in our market presence especially in the USA, the costs of which are reflected in a lower operating profit for Q2. We expect to see the benefits of this investment in subsequent periods.

    In March, the European Commission adopted the Commission Implementing Decision to amend the marketing authorisation for RUCONEST® to include self-administration using the RUCONEST® Administration Kit. This decision allows for self-administration of RUCONEST® for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed RUCONEST® Administration Kit in the comfort and privacy of their own homes or at any other place they choose, without the necessity of a healthcare professional (HCP) being present. The Administration Kit is now available for use in various EU markets, following approval of the Educational Materials by the local authorities in those markets.

    In May, we announced a major refinancing of most of the financial instruments taken out in order to complete the acquisition of the commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX). Pharming completed a new US$100 million finance agreement with Orbimed Advisors. The new facility has been used to redeem the Amortizing Convertible Bonds due 2017/2018 and to refinance the Company’s senior debt facility with Silicon Valley Bank and Kreos Capital, together with the associated prepayment fees, legal fees and other costs of the transaction. The loan, initially structured as a bridge facility, was replaced last week by a full loan agreement with a maturity date of July 2021 under the same terms and conditions. This refinance enabled the company to recover 115 million shares, which had been set aside to meet conversions of the Amortizing Convertible Bonds, thereby removing the risk of 24% dilution from conversion of these Bonds from existing shareholders. At the same time, we were able to lower the cash cost of the debt overall and to reduce significantly the non-cash accounting effects of the Amortizing Bonds, which amounted to almost €8 million in Q1 2017 alone.

    As expected, net profit was impacted by the one-off legal, accounting and other professional services costs resulting from the refinancing in May, which amounted to €16.1 million before non-cash financing expenses required to be shown under IFRS associated with the extinction of the Amortising Convertible Bonds 2017/2018 and replacement of the old debt facility.

    Based on the increased momentum in sales volumes, underlying improving trends in identifying and diagnosing patients, combined with better patient care and management practices, and a focus on specialty pharmacy customers, we expect to further increase sales. We will continue to control costs and investments to improve profitability and drive sustainable long-term growth. We continue to expect additional positive operating results for the remainder of the year. No further financial guidance is provided.

    Sijmen de Vries

    Chief Executive Officer

    Click here to download the full press release

    print
    Share This Story, Choose Your Platform!

    FacebookTwitterLinkedinRedditTumblrGoogle+PinterestVkEmail
  14. [verwijderd] 27 juli 2017 07:14
    Ik denk dat het derde kwartaal al hogere cijfers gaat laten zien, misschien kunnen ze dit jaar al de 80 a 90 miljoen laten zien .
    En voor het volgend jaar voorzie ik een stijging ver boven de 100 miljoen.
    Met de cijfers van nu ben ik tevreden die men in die korte tijd hebben weten te maken, de omslag is gaande nu alleen nog de acceleratie
  16. [verwijderd] 27 juli 2017 07:15
    quote:

    SijmendeVries schreef op 27 juli 2017 07:12:

    Goedemorgen Pharming-volgers,

    Hierbij de link naar het Halfjaarbericht van Pharming dat we zonet gedistribueerd hebben.

    Met vriendelijke groet,

    Sijmen de Vries, CEO Pharming Group NV

    www.lifespring.nl/view_web_version?da...
    U kunt het ook niet helpen,

    Gecondoleerd met uw halfjaar cijfers.
50.750 Posts
Pagina: «« 1 ... 1048 1049 1050 1051 1052 ... 2538 »» | Laatste |Omhoog ↑

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: volop groeimotoren voor Pharming
  2. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  3. Topman De Vries stopt bij Pharming
  4. Pharming start met Fase II klinische studie leniolisib
  5. Pharming: herstelpotentieel van 100%
  6. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak
  7. Micron-effect op de beurs? AEX gaat fraaie opening tegemoet, chipaandelen Azië vliegen
  8. Brits groen licht voor Joenja van Pharming
  9. Video: CEO tevreden over ontwikkelingen bij Pharming
  10. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10